Due to the approval and introduction of new ephedrine products there in 2018, North America held the largest market share in the entire industry. For instance, in March 2017, Akorn, Inc., a manufacturer of generic and branded pharmaceuticals, received FDA approval for its New Drug Application (NDA) for a single-dose ampule of an ephedrine sulphate infusion that is proven to treat hypotension that occurs after spinal anaesthesia. Ephedrine product introductions that are expanded are anticipated to influence Ephedrine Market growth in the European area.
For instance, the U.S. Food and Drug Administration granted approval to Avadel Pharmaceuticals, formerly known as Flamel Technologies, in April 2016 for Akovaz, an ephedrine sulphate infusion that will be used to treat hypotension that occurs during sedation.
